Pharmadrug Inc.
PHRX
CNSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -77.12% | 261.64% | |||
| Depreciation & Amortization | 3.41% | -2.22% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -55.25% | -49.53% | |||
| Operating Income | 55.25% | 49.53% | |||
| Income Before Tax | 24.88% | -1,532.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 24.88% | -1,532.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -25.42% | -79.33% | |||
| Net Income | 24.79% | -234.23% | |||
| EBIT | 55.25% | 49.53% | |||
| EBITDA | 77.12% | 57.25% | |||
| EPS Basic | 16.67% | -220.00% | |||
| Normalized Basic EPS | 25.00% | -500.00% | |||
| EPS Diluted | 16.67% | -220.00% | |||
| Normalized Diluted EPS | 25.00% | -500.00% | |||
| Average Basic Shares Outstanding | 0.43% | 4.33% | |||
| Average Diluted Shares Outstanding | 0.43% | 4.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||